PREDIX Luminal A - Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors. Part of a Platform of Translational Phase II Trials Based on Molecular Subtypes

Trial Profile

PREDIX Luminal A - Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors. Part of a Platform of Translational Phase II Trials Based on Molecular Subtypes

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Sep 2016

At a glance

  • Drugs Palbociclib (Primary) ; Anastrozole; Exemestane; Goserelin; Letrozole; Tamoxifen
  • Indications Breast cancer; Male breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Sep 2016 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
    • 07 Sep 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
    • 03 Nov 2015 New source identified and integrated (ClinicalTrials.gov NCT02592083).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top